<table rules="all" xmlns="urn:hl7-org:v3" xmlns:voc="urn:hl7-org:v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<tbody>
<tr>
<td colspan="2">
<content stylecode="bold">Bleeding times</content>
</td>
</tr>
<tr>
<td>
<content stylecode="italics">Clinical Impact:</content>
</td>
<td>Naproxen may decrease platelet aggregation and prolong bleeding time.</td>
</tr>
<tr>
<td>
<content stylecode="italics">Intervention:</content>
</td>
<td>This effect should be kept in mind when bleeding times are determined.</td>
</tr>
<tr>
<td colspan="2">
<content stylecode="bold">Porter-Silber test</content>
</td>
</tr>
<tr>
<td>
<content stylecode="italics">Clinical Impact:</content>
</td>
<td>The administration of naproxen may result in increased urinary values for 17-ketogenic steroids because of an interaction between the drug and/or its metabolites with m-di-nitrobenzene used in this assay.</td>
</tr>
<tr>
<td>
<content stylecode="italics">Intervention:</content>
</td>
<td>Although 17-hydroxy-corticosteroid measurements (Porter-Silber test) do not appear to be artifactually altered, it is suggested that therapy with NAPRELAN be temporarily discontinued 72 hours before adrenal function tests are performed if the Porter-Silber test is to be used.</td>
</tr>
<tr>
<td colspan="2">
<content stylecode="bold">Urinary assays of 5-hydroxy indoleacetic acid (5HIAA)</content>
</td>
</tr>
<tr>
<td>
<content stylecode="italics">Clinical Impact:</content>
</td>
<td>Naproxen may interfere with some urinary assays of 5-hydroxy indoleacetic acid (5HIAA).</td>
</tr>
<tr>
<td>
<content stylecode="italics">Intervention:</content>
</td>
<td>This effect should be kept in mind when urinary 5-hydroxy indoleacetic acid are determined.</td>
</tr>
</tbody>
</table>